טוען...
Targeting Host Cell Surface Nucleolin for RSV Therapy: Challenges and Opportunities
Nucleolin (NCL) has been reported as a cellular receptor for the human respiratory syncytial virus (RSV). We studied the effects of re-purposing AS1411, an anti-cancer compound that binds cell surface NCL, as a possible novel strategy for RSV therapy in vitro and in vivo. AS1411 was administered to...
שמור ב:
| הוצא לאור ב: | Vaccines (Basel) |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
MDPI
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5620558/ https://ncbi.nlm.nih.gov/pubmed/28925950 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/vaccines5030027 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|